Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bod Science Limited specializes in developing and commercializing innovative pharmaceutical products, particularly in the realm of specialty drugs. The company has a unique focus on rare diseases, which allows it to command higher pricing power and face less competition. Its operational footprint primarily spans Australia and select international markets, leveraging partnerships with local distributors.
Bod Science generates revenue through the sale of specialty pharmaceuticals, which often have higher margins due to limited competition and unique formulations. The company employs a direct-to-pharmacy distribution model, enhancing its pricing power and customer relationships. Its focus on rare diseases allows for a niche market strategy, reducing competitive pressures.
Regulatory approvals for new specialty drugs
Partnership announcements with larger pharmaceutical companies
Market expansion into new geographies, particularly Asia-Pacific
Clinical trial results for pipeline products
Regulatory changes that could impact drug approval processes
Technological disruptions in drug development methodologies
Emergence of generic alternatives for existing products
Increased competition from larger pharmaceutical companies entering the specialty drug market
Negative equity position due to accumulated losses
Low current ratio (0.34) indicating potential liquidity issues
moderate - As a healthcare provider, Bod Science's products are somewhat insulated from economic downturns, but overall healthcare spending can be influenced by GDP growth.
The company has minimal debt, so rising interest rates primarily affect its cost of capital for future expansions rather than current operations.
minimal
growth - Investors seeking high-growth opportunities in niche pharmaceutical markets.
high - The stock has demonstrated significant volatility, with a 1-year return of -85.0%.
